Lung Cancer Clinical Trials & Research at St. Joseph Health Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

St. Joseph Health Medical Group is currently enrolling patients for the following lung cancer clinical trials:

Non-Small Cell Lung Cancer
Small Cell Lung Cancer


Non-Small Cell Lung Cancer

Phase 2 Platform Study in Patients with advanced non-small lung cancer who progressed on First Line Osimertinib therapy (ORCHARD)

Treatment agent: Osimertinib
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03944772


Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Treatment agent: Osimertinib + Savolitinib
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03778229


Tepotinib Phase II in Non-small cell lung cancer (NSCLC) Haboring MET Alterations (VISION)

Treatment: Tepotinib
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT02864992


A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)

Treatment agent: Platinum doublet chemo + radiotherapy + pembrolizumab
PI: Ian Anderson, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links: clinicaltrials.gov NCT No: NCT03631784


Small Cell Lung Cancer

Study of Durvalumab + Tremelimuab, Durvalumab, and Placebo in Limited Stage Small- Cell Lung Cancer in Patients who Have Not progressed following concurrent chemoradiation therapy (ADRIATIC)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03703297


Seer-020201 (Pulmonary Nodules)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Manasa Vulchi, MD
Study Coordinator: Melissa​
NCT – NA


A Study of Repotrectinib( TPX-005) in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangments( TRIDENT-1)

Treatment: Oral repotrectinib
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03093116

Our Providers

Our Locations